GlassScriptPhysician profile
Jerzy Slomka
NPI 1467452904
$3,644.07
in general payments reported to CMS, 2019-2025
29 companies · $777 in 2025
The $777 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $174 · 2021: $282 · 2022: $493 · 2023: $852 · 2024: $546 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.78 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Sunovion Pharmaceuticals INC. | $387.65 | 2019-2022 | |
| Pfizer INC. | $333.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $303.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $302.22 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $244.39 | 2023-2025 | Gemtesa |
| Amgen INC. | $193.31 | 2019-2025 | Evenity, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.96 | 2023-2025 | Xifaxan |
| Lilly USA, LLC | $126.56 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Merck Sharp & Dohme LLC | $88.14 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Novo Nordisk INC | $85.77 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.34 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $70.32 | 2019-2022 | |
| Astellas Pharma US INC | $65.00 | 2022 | |
| Mylan Specialty L.P. | $61.55 | 2020-2024 | Yupelri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.30 | 2022-2025 | Jardiance, Tradjenta |
| Dexcom, INC. | $54.93 | 2023-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $52.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $47.83 | 2021-2023 | Bexsero, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $41.13 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.27 | 2022 | |
| Allergan, INC. | $31.21 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.81 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $21.68 | 2023 | Orladeyo |
| Viatris Specialty LLC | $16.34 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $16.02 | 2023 | Quviviq |
| Genentech USA, INC. | $15.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.74 | 2024 | Eliquis |
| Electromed, INC. | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerzy Slomka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.